Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 421-438 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 421 | Camphouse lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Camphouse after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says only a generic roundup mention was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 422 | Capsa AI lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Capsa AI after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 423 | CardNexus lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CardNexus after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says the reviewed sources does not provide direct company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 424 | CeQur lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CeQur after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 425 | CITIC Group lowweak | Opp 0 Risk 1 | Thesis: No reviewed sources-supported positive thesis is available. The reviewed sources explicitly says the summaries do not clearly connect CITIC Group to a qualifying space business. Why now: There is no current catalyst. Despite 4,475 article IDs considered, the reviewed sources reports zero article IDs after recent evidence window and zero evidence after recent evidence window. Caveats: Phase2 rationale references article IDs: and: as context, but no were provided in the reviewed sources. Very large raw mention universe does not imply conviction or thesis attractiveness. Possible name/alias ambiguity is unresolved by the reviewed sources. |
| 426 | COMSAT lowweak | Opp 0 Risk 1 | Thesis: No positive thesis is supported. The reviewed sources rationale says COMSAT appears only in the context of Intuitive Machines acquiring Goonhilly Earth Station/COMSAT, which is indirect and not sufficient for a company-specific opportunity view. Why now: No 90-day article summaries or evidence were available for COMSAT in these reviewed sources, so there is no supported timing catalyst. Caveats: Relations/context-only style mention should not be used as counterparty propagation evidence. Phase2 rationale references article ids: and: but no or summaries are provided in the reviewed sources. No direct evidence were available after recent evidence window. |
| 427 | EaglePicher Technologies lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale says EaglePicher is a key player in space batteries and that its systems were on NASA CLPS lunar lander missions, but no retained direct positive evidence or article summaries are available here. Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Caveats: Phase-2 rationale references article, but the reviewed sources does not include the article summary or retained evidence. Supplier relevance to the space ecosystem does not by itself justify an opportunity score without current retained evidence. Recency is uncertain because the supporting substantive claims are not preserved in the recent evidence window evidence set. |
| 428 | Element U.S. Space & Defense lowweak | Opp 0 Risk 1 | Thesis: The reviewed sources only indicates service/testing relevance in a Sidus-related context, and it contains no retained direct positive evidence with inside the recent evidence window, so there is no supported opportunity thesis. Why now: Why now is absent because only 2 articles were considered and none survived the 90-day filter; there is no current evidence basis for a 1 year+ directional call. Caveats: Coverage is extremely sparse. The only described relation is context/service oriented and relations are context-only unless policy-gated. No post-cutoff evidence available. |
| 429 | IHI Corporation lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale references IHI benefiting from ICEYE SAR satellites and planning multi-sensor integration, but no retained direct evidence or article summaries are present here. Why now: There is no current why-now signal in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Caveats: Phase-2 rationale references article: but the actual retained evidence is absent from these reviewed sources. The rationale itself frames IHI more as a beneficiary/customer than clearly as the core space operator, which weakens directional use even if the older article were available. |
| 430 | Island Green Capital lowweak | Opp 0 Risk 1 | Thesis: No direct positive evidence is available, and the reviewed sources say the included summaries do not clearly establish what Island Green Capital is. Why now: No timing-based catalyst is supported because no post-recent evidence window evidence were available. Caveats: Phase2 rationale references article IDs: and: but no were provided in the reviewed sources. Reviewed evidence states summaries were about Molten Ventures and Isar Aerospace rather than clearly about Island Green Capital. Context-only mentions cannot support propagation. |
| 431 | OneWeb lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence because there are no direct positive evidence and no articles retained after the 90-day recent evidence window. Why now: There is no current why-now signal in the reviewed evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after dedupe/recent evidence window. Caveats: Phase-2 rationale references article: but that article content is not provided here and no retained evidence remain after recent evidence window. Membership review status is not directional proof. Absence of evidence should not be interpreted as absence of business activity. |
| 432 | Starfighters Space Inc. lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale describes air-launch and testing platform exposure, but no retained direct positive evidence or article summaries are provided here. Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite substantial historical article count. Caveats: Phase-2 rationale references articles: and: but their content is not included here. Historical mention density is not conviction. Public listing/ticker presence does not create a directional thesis without retained evidence. |
| 433 | Starlab Space lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale notes a letter of intent related to debris removal services, but no direct retained evidence row or article summary is provided in these reviewed sources. Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window. Caveats: Phase-2 rationale references article: but the underlying article details are not included here. A referenced letter of intent, without retained evidence details or timing, is insufficient for a 1 year+ directional ranking. Private-company status may limit visibility, but that is not itself a thesis. |
| 434 | SWISSto12 lowweak | Opp 0 Risk 1 | Thesis: No supported positive thesis. The reviewed sources say SWISSto12 is only mentioned in passing in an article about SpaceLocker, which is provisional single-article context and not company-specific evidence, unavailable in reviewed sources). Why now: There is no identifiable catalyst because the reviewed sources provide only a passing mention and no direct event or fact evidence. Caveats: No current evidence is provided for. Support level is provisional single-article context only. No evidence available after recent evidence window. |
| 435 | Veact lowweak | Opp 0 Risk 1 | Thesis: No positive thesis is supported. Veact appears only via a broad funding roundup and is not linked to a space-specific category in the reviewed sources. Why now: No why-now catalyst is supported because the reviewed sources contain no post-recent evidence window evidence. Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. A broad funding roundup is not enough to establish thesis direction. Coverage data shows articles after recent evidence window = 0. |
| 436 | Volteum lowweak | Opp 0 Risk 1 | Thesis: No direct positive evidence is available. The reviewed sources only says Volteum surfaced from a general funding roundup with no space-specific linkage. Why now: No catalyst is supported in the reviewed sources due to zero post-recent evidence window evidence. Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. Funding-roundup presence alone is not directional proof. Evidence strength remains minimal. |
| 437 | Zaro lowweak | Opp 0 Risk 1 | Thesis: No reviewed sources-supported positive thesis is available. Zaro is only listed in a general funding roundup with no direct linkage to a qualifying space thesis. Why now: There is no current or durable catalyst supported by the reviewed sources because no evidence survived into the available post-recent evidence window set. Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. General funding-roundup context is weaker than direct event or fact evidence. Coverage remains insufficient for a directional call. |
| 438 | Zone14 lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be supported from the reviewed sources because there is no direct positive evidence available for Zone14 within the 90-day recent evidence window. Why now: There is no current company-specific catalyst visible in the reviewed sources. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window for Zone14; the membership note says it appears only through a broad funding roundup and lacks company-specific evidence tied to the listed scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. Company appears only in review status with low membership confidence, which is not directional evidence. |
Risk view
Showing rows 81-100 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 81 | Interlune lowweak | Opp 5 Risk 3 | Thesis: The company also carries execution risk because the reviewed sources provide no further retained evidence on milestone completion, follow-on awards, commercialization timing, or technical results. A single contract supports relevance but does not prove scalable economics. Why now: The key 'why now' is the cited NASA contract in article: but the reviewed sources does not include the article summary or, so exact date and latest status are not visible here. Caveats: Opportunity case relies on membership rationale rather than included direct article evidence. A $6.9M contract is positive validation, but contract size alone may not be enough to de-risk a lunar-resource business. No negative evidence is provided, so risk mostly reflects execution uncertainty. |
| 82 | IonQ lowweak | Opp 3 Risk 3 | Thesis: Risk stems from thesis leakage: the reviewed sources frames IonQ primarily as parent/acquirer, while the strongest space-specific evidence appears to sit at subsidiary level, so investors could overstate IonQ's direct space-business impact based on insufficient company-specific proof. Why now: Potential 'why now' would be the referenced space-subsidiary contract pathway, but recency and direct materiality to IonQ are not validated in available evidence for the 90-day recent evidence window. Caveats: Phase-2 rationale references and: but no or summaries are provided in the reviewed sources. Relations and counterparty propagation are not allowed by default. Coverage debug shows zero evidence after recent evidence window despite a large article universe. |
| 83 | Iridium Communications Inc. lowmedium | Opp 5 Risk 3 | Thesis: Risk is moderate-low because there is no direct adverse evidence, but the reviewed sources lack recent company-specific contract, financing, or product milestone catalysts, so the case depends more on strategic position than on fresh business acceleration. Why now: The current support is an April 3, 2026 article-level overview of Iridium’s constellation and service footprint rather than a new event, so timing fit is only medium. Evidence
Caveats: Evidence is supporting article context, not a fresh contract or earnings-linked milestone. |
| 84 | Kepler mediummedium | Opp 6 Risk 3 | Thesis: Risk remains moderate because the evidence is primarily a company-source article and supporting article context rather than independent dated event evidence. The reviewed sources show no adverse developments, but also limited third-party confirmation. Why now: The latest visible evidence is dated June 23, 2026, making the milestone recent within the 90-day recent evidence window. The article explicitly frames this as the beginning of an operational network, which is more relevant to a 1 year+ horizon than a short-lived announcement. Evidence
Caveats: Primary evidence is from Kepler's own site. No direct contract, revenue, or financing detail is provided in the visible evidence. Same article appears in both representative and weak-context forms, which is not independent confirmation. |
| 85 | Kepler Aerospace lowweak | Opp 3 Risk 3 | Thesis: There is no direct negative evidence available. The main risk is that the business description is broad but unsupported by current, citable post-recent evidence window evidence, leaving commercialization and scale uncertain. Why now: No current catalyst is established. Membership support references article ID: but the reviewed sources provide no and shows no evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary. Context includes relation/fact counts in support statistics, but relations are context-only and cannot be propagated as operating proof. |
| 86 | L3Harris Technologies mediummedium | Opp 6 Risk 3 | Thesis: Risk is lower than many peers in these reviewed sources because there is no cited direct adverse evidence, but the ranking is capped by limited fresh company-specific evidence within the 90-day window and reliance on supporting article context rather than detailed award economics attributable specifically to L3Harris. Why now: The recent timing anchor is the April 8, 2026 Andromeda article. Older 2020 MOSSAIC history exists in the reviewed sources but should not drive the current timing view because it is outside the recent evidence window and materially older than the current contract context. Evidence
Caveats: Current opportunity case depends on supporting article context rather than available direct positive events. The reviewed sources includes an older 2020 contract article, but that is not recent support for 'why now'. |
| 87 | Loft Orbital mediummedium | Opp 7 Risk 3 | Thesis: Risk exists because the positive case is largely supporting article context from external supporting source sources rather than direct dated events in the reviewed sources, and execution remains significant given a 10-satellite constellation deployment and launch timeline. But there is no retained material adverse evidence. Why now: Why now is credible for a 1 year+ horizon because several dated articles from 2026 establish a recent contract win and near-forward deployment timeline: Loft announced on April 30, 2026 a multi-year CNES contract worth up to tens of millions of euros with first satellite scheduled to launch in Q4 2026. Via Satellite on May 1, 2026 described a 10-satellite EO constellation under that contract. SpaceNews on May 5, 2026 said Loft is expanding into 'full-service constellation deals'. Evidence
Caveats: Most retained support is supporting article context, which the reviewed sources treats as bounded context and weaker than direct dated event/fact evidence. Several favorable funding articles for Loft are dated January 2025 and were dropped by the 90-day recent evidence window, so they should not drive the current score. Execution risk remains around deploying the constellation and meeting the stated 2026 launch timing. |
| 88 | MDA Space Ltd. lowweak | Opp 4 Risk 3 | Thesis: Risk is moderate because the available evidence is entirely undated external article context, making recency and state-of-business uncertain. Why now: Why-now is weak because both available representative articles are undated, so current timing and whether these items remain incremental versus already absorbed is uncertain Evidence
Caveats: Both cited articles are undated; recency is uncertain. Support is weak and based on article context, not direct positive events. No material adverse evidence is available, but no strong current catalyst is validated either. |
| 89 | Modul8 lowweak | Opp 4 Risk 3 | Thesis: Risk remains moderate because the reviewed sources supplies no available positive evidence after recent evidence window to confirm timing, contract status, or deployment progress; mission-heavy lunar communications programs can be timing-sensitive, but these reviewed sources gives no adverse proof either. Why now: Among sparse names, the stated combination of funding plus lunar communications program exposure could matter over 1 year+, but recency cannot be validated from served evidence. Caveats: The strongest claims are only in membership rationale and not backed by citeable -bearing evidence in the reviewed sources. No negative evidence does not equal low fundamental risk. |
| 90 | Muon Space lowweak | Opp 3 Risk 3 | Thesis: Risk is balanced with opportunity because the available evidence is mostly weak supporting article context rather than direct contract, financing, or milestone evidence, leaving business traction and near-medium term scaling uncertain. Why now: The most recent dated context is a May 22, 2026 job posting indicating contracting and legal operations needs, which may imply organizational buildout but is weak evidence for a major catalyst. Evidence
Caveats: The reviewed sources contain no direct positive or negative company-specific events. The May 22, 2026 job posting is operational context, not proof of revenue or contracts. Citation |
| 91 | NordSpace Corp. lowweak | Opp 3 Risk 3 | Thesis: No direct adverse evidence is available, but development-stage rocket businesses carry obvious execution dependency; in these reviewed sources that risk cannot be upgraded to high because the evidence does not show a specific setback, only insufficient current confirmation. Why now: The only directional clue is the membership-support article reference: but the reviewed sources includes no, no summary, and no available post-recent evidence window evidence, so timing and durability are uncertain. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary. Opportunity case relies on generic funding support mention without current milestone evidence. |
| 92 | Northrop Grumman Corp mediumstrong | Opp 8 Risk 3 | Thesis: Risk is present but comparatively modest in the reviewed sources because no material adverse event is cited. The main risk is that the evidence is largely supporting article context and program participation, so exact economic contribution, timing, and competitive share are not fully established here. Why now: The setup is current and cumulative: April 8, 2026 Andromeda participation, June 1, 2026 Golden Dome interceptor partnership, and June 22, 2026 award of a $398M protected satcom contract all fall within the 90-day recent evidence window and point to sustained momentum. Evidence
Caveats: The reviewed sources does not provide direct business impact breakdowns beyond the $398M contract article. Some support is supporting article context rather than dated events. |
| 93 | NorthStar Earth & Space lowweak | Opp 4 Risk 3 | Thesis: Risk is moderate because evidence coverage is very thin, and the reviewed sources offers mainly context that the company planned to go public via SPAC, without stronger direct proof on operational milestones or contract conversion in this company row. Why now: The only dated evidence in this row is an April 27, 2026 article-level summary stating NorthStar Earth & Space plans to go public in a SPAC deal at a $300 million valuation. That may matter over a 1 year+ horizon, but the reviewed sources does not provide stronger company-specific direct evidence here. Evidence
Caveats: Coverage is extremely thin in this row: only one external article and no direct positive or negative dated events. The phase-2 rationale mentions a CAD$40M+ Royal Canadian Air Force contract, but that contract evidence is not directly surfaced in the available evidence fields for this output row, so it should not be elevated beyond the membership rationale. |
| 94 | Open Cosmos mediummedium | Opp 7 Risk 3 | Thesis: Risk is present but not strongly evidenced as negative news. The main risks are that the evidence is supporting article context rather than direct events, and one supporting item concerns spacecraft supply to a military mission rather than direct revenue or contract award to Open Cosmos. Why now: The timing is favorable for a 1 year+ horizon because the latest dated evidence on June 17, 2026 indicates market entry and operation of the first telecom satellites, which can matter over a multi-quarter rollout period. A prior April 8, 2026 article also shows Open Cosmos spacecraft being used in the Orpheus UK military mission, adding defense-adjacent relevance. These dates are source dates extracted from the article summaries. Evidence
Caveats: Evidence is external article context and weak-context rows, not direct positive events. Same-article repeated rows are not independent confirmation. |
| 95 | Orbital lowweak | Opp 4 Risk 3 | Thesis: Risk is also meaningful because the same article describes an early-stage startup with only a $5 million pre-seed raise pursuing an extremely ambitious plan involving an in-orbit demo next year and more than 100,000 orbital data centers, which raises execution and scale risk, although this is supporting article context rather than direct adverse evidence, June 10, 2026). Why now: The recency is relatively fresh: the is based on June 10, 2026, inside the 90-day recent evidence window, and it frames both new capital and a next-year demo as near-to-medium-term strategic milestones. Evidence
Caveats: All retained evidence is weak context supporting article context; there is no direct positive event/fact available. Same-article repeated rows are not independent confirmation. The opportunity case depends on an early-stage roadmap and financing announcement; commercial traction is not directly evidenced in retained rows. |
| 96 | Orbital Recovery Crew lowweak | Opp 3 Risk 3 | Thesis: Risk is also material because the evidence is limited to the company's own site and supporting article context, with no independent retained event evidence for contracts, missions, financing, customers, or regulatory outcomes; the same page also conditions service availability on manifest availability and continuing cooperation of regulatory bodies. Why now: The only retained evidence is a page with May 21, 2026, within the 90-day window, indicating recent discoverable claims of operations and service scope, but not a third-party validated catalyst. Evidence
Caveats: Evidence is company-site article context, not independent confirmation. No direct positive or negative dated events are available. Same-article repeated rows are not independent confirmation. |
| 97 | Overview Energy lowweak | Opp 4 Risk 3 | Thesis: The technology area appears highly ambitious and execution-sensitive, but no direct negative evidence is provided in the reviewed sources. Why now: The likely catalyst is the reported Air Force contract, yet the reviewed sources gives no retained article summary or evidence row to establish recency or contract scale. Caveats: Phase2 membership rationale references: but no article summary or evidence are available. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 98 | Pacific Defense lowweak | Opp 4 Risk 3 | Thesis: Despite the favorable context, the reviewed sources contain no post-recent evidence window evidence, no -backed article summary, and no fresh proof of follow-on contracts or operational success after the demo; that limits conviction and leaves execution risk unresolved. Why now: The company appears more advanced than several peers because the reviewed sources references an on-orbit demo under contract, but there is no citable recency signal beyond membership support article ID: and no available evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary for citation. Opportunity score is relative within a weak-evidence batch, not high absolute conviction. |
| 99 | Payload Aerospace, S.A. lowweak | Opp 2 Risk 3 | Thesis: Main risk is evidence opacity and recency uncertainty rather than documented adverse events. The reviewed sources show one article considered but zero article IDs after recent evidence window and zero evidence available after recent evidence window, so business-state visibility is poor. Why now: Why now is weak because the reviewed sources' coverage debug shows zero article IDs after the March 29, 2026 cutoff and zero evidence after recent evidence window; any older fundraising context may no longer capture current business state. See support references listing article in the membership rationale, but no or article detail is provided in the reviewed sources, so recency and context cannot be independently assessed. Caveats: No -bearing article detail is provided for the fundraising support article, so factual claims beyond the membership rationale cannot be expanded. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0, limiting confidence. |
| 100 | Planet Labs PBC lowweak | Opp 3 Risk 3 | Thesis: Risk is moderate because the reviewed sources lack recent direct evidence on contracts, growth, financing, or setbacks, leaving the current business trajectory uncertain. Why now: Why-now is weak: the only in-window evidence is an April 5, 2026 startup-listing article describing Planet as operating its own satellite constellation and geospatial analytics platform, which is durable context but not a clear catalyst. Evidence
Caveats: Evidence is only supporting article context, not direct company event or fact evidence with strong materiality. No direct positive or negative dated events are available. This is a low-conviction watchlist name in these reviewed sources. |